Natasha E. Daughtrey

Representative matters include:

• Representing Celltrion in ongoing patent infringement litigation brought by Genentech and others under the Biologics Price Competition and Innovation Act related to Celltrion’s biosimilar rituximab product, Truxima®.
• Representing Teva in an ongoing patent infringement litigation against Eli Lilly and Company related to Eli Lilly’s application to the FDA to market the antibody galcanezumab for the treatment of migraine.
• Represented Spatz in patent infringement action brought by L’Oréal USA, Inc. related to cosmetics.
• Represented AMAG Pharmaceuticals in patent infringement action against Sandoz Inc. related to Sandoz’s proposed generic version of Feraheme® (ferumoxytol) for the treatment of iron-deficiency anemia.
• Represented an individual in a patent infringement and unfair competition case related to electrical transmission lines.
• Represented Actavis in a patent infringement action filed by Valeant Pharmaceuticals Int’l and others under the Hatch-Waxman Act relating to Actavis’s filing of an abbreviated new drug application for generic versions of Valeant’s drug UCERIS®.At trial, the Court granted Actavis’s motion for judgment of non-infringement under Rule 52(c).
• Represented Teva in Hatch-Waxman patent infringement litigation brought by Genzyme in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).
• Represented Lupin in patent infringement litigation under the Hatch-Waxman Act in response to Lupin’s filing of an abbreviated new drug application seeking approval to market a generic version of Senju’s Prolensa® (bromfenac ophthalmic solution) medication.
• Represented Roxane in a patent infringement litigation filed by Prometheus in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’s IBS treatment drug, Lotronex® (alosetron hydrochloride). After a bench trial, the District Court found in favor of Roxane that Prometheus’s patent was invalid.